Introduction {#s1}
============

Inflammation of the synovium, particularly the bone marrow, measured using MRI, has been identified as a prognostic indicator of structural joint damage in patients with rheumatoid arthritis (RA).[@R1] Inhibition of this damage at an early stage in the disease course is desirable to limit disability[@R4] and impact on general health and quality of life.[@R5]

Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of RA. The efficacy and safety of tofacitinib 5 and 10 mg twice daily in patients with active moderate-to-severe RA has been demonstrated in randomised, double-blind, phase 2[@R6] and phase 3[@R11] studies of up to 24 months duration and in open-label, long-term extension studies with up to 96 months of observation.[@R17] The inhibition of structural damage in patients who received tofacitinib has been shown using plain-film radiography.[@R14] [@R15]

MRI measures provide improved sensitivity versus conventional radiography.[@R18] Bone marrow oedema (BME) and synovitis, measured using MRI, have been shown to be highly sensitive to treatment with conventional synthetic disease-modifying antirheumatic drugs.[@R21] However, few randomised clinical trials have been published using MRI outcomes as primary endpoints in patients with early RA.[@R21] [@R23] [@R26] The validated, semiquantitative assessment of multiple pathologies using the Outcome Measures in Rheumatology Clinical Trials (OMERACT) RA MRI score (RAMRIS)[@R29] has become the standard for MRI trials.[@R20] Quantitative MRI measures offer the opportunity to improve on the responsiveness of semiquantitative scoring. Dynamic contrast-enhanced (DCE) MRI measurements show strong correlation with histological assessments of synovitis[@R30] and have demonstrated sensitivity in detecting therapy-induced changes in synovitis in patients with early RA.[@R31] [@R32] Preliminary work with active appearance modelling (AAM)[@R33] RA MRI quantification (RAMRIQ) of all involved joint tissues has suggested improved responsiveness over RAMRIS.[@R34]

Patients with early RA have participated in previous studies of tofacitinib, although the lowest mean duration of RA was approximately 3 years.[@R14] This is the first study to explore the effects of tofacitinib, as monotherapy or in combination with methotrexate (MTX; vs MTX with placebo), on a range of highly sensitive MRI endpoints, exclusively in patients with early RA.

Methods {#s2}
=======

Study design and conduct {#s2a}
------------------------

This was an exploratory, phase 2, randomised, double-blind, double-dummy, parallel-group study (A3921068; NCT01164579), conducted at 24 centres in Central and Latin America, Europe and the USA (25 October 2010--5 November 2013). Study end was the month 12 visit or early termination for patients who discontinued.

Randomisation and treatment {#s2b}
---------------------------

At baseline, patients were randomised 1:1:1 using an automated web/telephone randomisation system to tofacitinib 10 mg twice daily with MTX, tofacitinib 10 mg twice daily with placebo (tofacitinib monotherapy) or MTX with placebo (MTX monotherapy), for 12 months. Tofacitinib 10 mg twice daily was administered orally as two 5 mg tablets twice daily. MTX was administered orally in capsule form and titrated, if tolerated, from 10 mg once weekly (4×2.5 mg capsules) to 15 mg once weekly (6×2.5 mg capsules) at the end of month 1, and 20 mg once weekly (8×2.5 mg capsules) at the end of month 2. Placebo was matched to tofacitinib or MTX, according to randomisation.

Patients {#s2c}
--------

Eligible patients were aged ≥18 years; active RA (\>6 tender/painful joints/\>6 swollen joints) of ≤2 years duration since diagnosis; erythrocyte sedimentation rate (ESR; Westergren method) \>28 mm/h, or C-reactive protein \>7 mg/L. Patients were generally MTX-naive, although \<3 weekly doses of MTX were permitted after a 4-week washout of MTX, unless MTX had been stopped due to a related adverse event (AE). Key eligibility criteria included unequivocal evidence of ≥1 joint erosion on hand/wrist radiographs (assessed at the study centre), plus clinical evidence of synovitis (tenderness/pain or swelling, or both; confirmed by MRI at the study centre); see online supplementary materials for additional details.

Patients were excluded if they had received prior biological disease-modifying antirheumatic drugs therapy; background arthritis therapy is detailed in the supplementary materials. Other exclusion criteria included replacement of an metacarpophalangeal (MCP) or wrist joint within the index wrist or hand, any contraindications to MRI (glomerular filtration rate \<60 mL/min) or previous reaction to gadolinium contrast agent. Patients with malignancies, lymphoproliferative disorder, evidence of untreated latent or active tuberculosis, serious infection ≤6 months previous or infection requiring antimicrobial therapy ≤2 weeks previous were also excluded.

MRI assessments {#s2d}
---------------

MRIs were obtained at screening, and at months 1, 3, 6 and 12, using clinical scanners (1.5  or 3.0 T). The same scanner was used serially at any given centre. The contrast agent (0.1 mmol/kg gadolinium) was administered intravenously with an infusion pump. Images included coronal short tau inversion recovery images, pre-contrast and post-contrast coronal T1-weighted (T1w) fat-suppressed gradient echo images, axial DCE T1w gradient echo images and post-contrast axial T1w fat-suppressed spin echo images. Example images are shown in the online [supplementary materials](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-208267/-/DC1).

### RAMRIS {#s2d1}

MRI BME, synovitis and bone erosions in the index hand (MCP joints 1--5) and wrist were scored according to OMERACT RAMRIS[@R35] by one centralised reader blinded to time sequence and treatment. The presence of any MRI-detected synovitis in the studied joints that were evaluated with RAMRIS (wrist and MCP joints 2--5) was used as MRI confirmation of clinical inclusion.

### RAMRIQ {#s2d2}

RAMRIQ measurements of BME, synovitis and erosions in the wrist and MCP joints 2--5 were performed by Imorphics (Manchester, UK) using automated methods. RAMRIQ assessed the same pathologies and joints (excepting MCP1) as RAMRIS, allowing for direct comparison of results obtained using the two methods. Bones were automatically identified in pre-contrast, coronal T1 images using AAMs.[@R33] [@R36] Joint capsules and soft tissues were also segmented with AAMs, providing consistent 3D regions of interest (ROI) for synovial enhancement across all time points. Oedema volume was defined as non-erosion contrast-enhancing voxels inside the bone. Synovial volume was calculated as voxels that enhance within each ROI. Erosion volume was identified inside the bone surfaces using voxel-based classification. The volume of BME and erosions was normalised to total bone volume for statistical analysis.

### DCE MRI {#s2d3}

DCE MRI was captured for the wrist only. ROIs were defined by a radiologist within the area encompassing the distal radioulnar joint, the radiocarpal joint and the intercarpal--carpometacarpophalangeal joints. The number of enhancing voxels (N~Vox~), initial rate of enhancement (IRE) and maximum enhancement (E~Max~),with plateau and washout patterns, were automatically extracted from ROIs and the sum (N~Vox~) or average (IRE and E~Max~) of values across three user-defined ROIs was determined using the Dynamika software package (Image Analysis, London, UK[@R37]).

Endpoints {#s2e}
---------

The co-primary endpoints were change from baseline in RAMRIS BME at month 6, and change from baseline in synovitis at month 3, in wrist and MCP joints.

Changes from baseline in RAMRIS BME (except month 6), synovitis (except month 3) and RAMRIS erosions at months 1, 3, 6 and 12 were assessed as secondary endpoints. Exploratory endpoints included RAMRIQ assessments of BME, synovitis and erosions; DCE MRI assessment of N~Vox~, IRE and E~Max~; and proportions of patients with/without progression based on RAMRIS BME, synovitis and erosions.

Radiographic and clinical endpoints {#s2f}
-----------------------------------

Posteroanterior hand/wrist and anteroposterior foot radiographs at baseline, month 6 and month 12, were assessed as secondary endpoints using the van der Heijde modification of the total Sharp score (mTSS)---range 0--488, with higher scores indicating greater structural joint damage.[@R38] Radiographs were scored by a centralised reader blinded to time sequence and treatment received.

Clinical endpoints included American College of Rheumatology (ACR)20, ACR50 and ACR70 responses; proportion of patients achieving a Disease Activity Score (DAS28-4\[ESR\]) \<2.6 (remission) or ≤3.2 (low disease activity); and improvement from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) score ≥0.22.

Safety assessments {#s2g}
------------------

AEs and clinical laboratory abnormalities were recorded. Medical Dictionary for Regulatory Activities V.16.1 was used.

Statistical analyses {#s2h}
--------------------

This was an exploratory study. Sample size was determined by change from baseline in RAMRIS BME score at month 6 and RAMRIS synovitis score at month 3. A sample size of 30 patients per arm provided \>80% probability to show a statistical difference between arms at the two-sided α of 0.1. Owing to an observed dropout rate of ∼20%, approximately 110 patients were to be enrolled to obtain 90 evaluable patients for the primary endpoint analysis. Given the exploratory nature of the study, statistical significance was assessed at the 10% (two-sided) level. For reporting purposes, treatment differences with p\<0.05 (vs MTX monotherapy) were considered significant.

The evaluable set---all patients who were randomised to study treatment, received ≥1 dose of randomised investigational drug and had available data at baseline and the indicated time point---was used for the efficacy analyses.

Primary and secondary continuous efficacy endpoints were assessed using a mixed-effect model for repeated measures, with treatment arms as factors and baseline as a covariate. Categorical endpoints were summarised by frequency (n, %). For efficacy endpoints, 90% CIs were included for the difference in proportions between the treatment arms. Procedures for handling missing MRI values are provided in the online [supplementary materials](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-208267/-/DC1).

Cumulative probability plots examined the distribution of changes from baseline in OMERACT RAMRIS measures and van der Heijde mTSS. The smallest detectable changes (SDCs) for RAMRIS BME, synovitis and bone erosion measurements were determined according to the method described by Bruynesteyn *et al*[@R39] using month 6 MRI data from 10 patients; read twice by the same reader with \>4 weeks between readings to minimise any recall bias. SDCs for RAMRIS BME, synovitis and erosion scores were 1.85, 2.77 and 0.85, respectively.

Results {#s3}
=======

Patient disposition and demographics {#s3a}
------------------------------------

Of 109 patients randomised, 36 received tofacitinib with MTX, 36 received tofacitinib monotherapy and 37 received MTX monotherapy ([figure 1](#ANNRHEUMDIS2015208267F1){ref-type="fig"}). Baseline demographics and disease characteristics were generally well balanced between groups ([table 1](#ANNRHEUMDIS2015208267TB1){ref-type="table"}). Fewer patients who received MTX monotherapy completed the study (58.3% (n=21)) versus those who received tofacitinib with MTX (77.8% (n=28)) or tofacitinib monotherapy (75.0% (n=27)).

###### 

Summary of patient demographics and baseline characteristics

  Parameter                                           Tofacitinib 10 mg twice daily + MTX (N=36)   Tofacitinib 10 mg twice daily monotherapy (N=36)   MTX monotherapy (N=37)
  --------------------------------------------------- -------------------------------------------- -------------------------------------------------- ------------------------
  Age, mean (SD)                                      47.8 (12.3)                                  50.8 (12.8)                                        47.8 (11.6)
  Females, %                                          86.1                                         83.3                                               78.4
  Mean duration of disease, years (range)             0.8 (0.1--2.2)                               0.8 (0.1--8.5)                                     0.6 (0.1--1.9)
  Positive for rheumatoid factor, n/N (%)             26/34 (76.5)                                 27/35 (77.1)                                       27/37 (73.0)
  Anti-CCP positive, n/N (%)                          27/34 (79.4)                                 27/35 (77.1)                                       30/37 (81.8)
  Swollen joint count, mean (range)                   13.4 (0.0--32.0)                             15.3 (4.0--46.0)                                   14.4 (6.0--39.0)
  Tender joint count, mean (range)                    20.6 (0.0--57.0)                             20.9 (4.0--53.0)                                   20.5 (9.0--52.0)
  DAS28-4(ESR), mean (SD)\*                           6.3 (0.9)                                    6.5 (0.8)                                          6.4 (0.8)
  HAQ-DI score, mean (SD)\*                           1.5 (0.8)                                    1.5 (0.6)                                          1.5 (0.7)
  RAMRIS, mean (SD)†                                                                                                                                  
   BME                                                1.9 (3.7)                                    2.6 (3.7)                                          2.2 (5.1)
   Synovitis                                          5.8 (3.8)                                    5.7 (3.5)                                          5.3 (3.9)
   Bone erosions                                      9.4 (10.8)                                   7.5 (7.6)                                          12.2 (14.9)
  RAMRIQ, mean (SD)\*                                                                                                                                 
   BME                                                1.4 (2.8)                                    1.1 (2.7)                                          1.4 (2.7)
   Synovitis                                          7750.4 (5432.8)                              7971.8 (5510.1)                                    6980.7 (6304.8)
   Bone erosions                                      1.6 (0.9)                                    1.6 (0.8)                                          1.9 (1.3)
  DCE MRI N~Vox~, mean (SD)‡                          3013.6 (3605.6)                              2767.6 (2140.2)                                    3079.8 (3704.9)
  Radiographic evaluations, mean (SD)†                                                                                                                
   van der Heijde mTSS                                13.0 (21.7)                                  12.6 (26.0)                                        13.7 (26.0)
   JSN component score                                6.9 (13.3)                                   5.7 (15.0)                                         6.1 (12.7)
   Erosion component score                            6.1 (9.3)                                    6.9 (11.8)                                         7.6 (14.3)
  Prior MTX, n (%)§                                   0 (0.0)                                      2 (5.6)                                            4 (10.8)
  Prior/concomitant systemic corticosteroids, n (%)   20 (55.6)                                    16 (44.4)                                          21 (56.8)

\*Evaluable set: tofacitinib with MTX (N=36), tofacitinib monotherapy (N=36), MTX monotherapy (N=37).

†Evaluable set: tofacitinib with MTX (N=34), tofacitinib monotherapy (N=36), MTX monotherapy (N=37).

‡Evaluable set: tofacitinib with MTX (N=34), tofacitinib monotherapy (N=32), MTX monotherapy (N=32).

§Patients who had received \<3 weekly doses of MTX were permitted to participate following a 4-week washout of MTX unless MTX had been stopped due to a related adverse event.

BME, bone marrow Oedema; CCP, cyclic-citrullinated peptide; DAS28-4(ESR), Disease Activity Score in 28 joints with 4 variables including erythrocyte sedimentation rate; DCE MRI, dynamic contrast-enhanced MRI; HAQ-DI, Health Assessment Questionnaire-Disability Index; JSN, joint space narrowing; MTX, methotrexate; mTSS, van der Heijde modification of the total Sharp score; N~Vox~, number of enhancing voxels; RAMRIQ, quantitative rheumatoid arthritis MRI score; RAMRIS, rheumatoid arthritis MRI score.

![Patient disposition. ^a^Mean dose of methotrexate (MTX) at month 3 was 18.3 mg weekly; ^b^mean dose of MTX at month 3 was 19.0 mg weekly; ^c^could not attend scheduled visits due to work. AE, adverse event; BID, twice daily; N, number of patients in population or analysis set; n, number of patients with an event.](annrheumdis-2015-208267f01){#ANNRHEUMDIS2015208267F1}

Co-primary endpoints {#s3b}
--------------------

Treatment differences (90% CI) in RAMRIS BME at month 6 were −1.55 (−2.52 to −0.58) for tofacitinib with MTX and −1.74 (−2.72 to −0.76) for tofacitinib monotherapy (both p\<0.01 vs MTX monotherapy; [figure 2](#ANNRHEUMDIS2015208267F2){ref-type="fig"}A). Corresponding changes from baseline in RAMRIS synovitis score at month 3 were −0.63 (−1.58 to 0.31; p=0.27) and −0.52 (−1.46 to 0.41; p=0.36) ([figure 2](#ANNRHEUMDIS2015208267F2){ref-type="fig"}B).

![Least squares (LS) mean change from baseline in wrist and metacarpophalangeal (MCP): (A) rheumatoid arthritis MRI score (RAMRIS) bone marrow oedema (BME), (B) RAMRIS synovitis, (C) RAMRIS bone erosions, (D) quantitative rheumatoid arthritis MRI score (RAMRIQ) BME, (E) RAMRIQ synovitis, (F) RAMRIQ bone erosions and wrist (G) dynamic contrast-enhanced MRI (DCE MRI) number of enhancing voxels (N~Vox~) (evaluable set). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001 vs methotrexate (MTX) monotherapy, using a mixed-effect model for repeated measures. MRI measurements were based on one hand (most symptomatic at baseline). RAMRIS and RAMRIQ scores relate to MRIs of the index hand (MCP joints 1--5 and 2--5, respectively) and wrist. DCE MRI measurements relate to MRIs of the index wrist using regions of interest (ROIs) defined within the area encompassing the distal radioulnar joint, the radiocarpal joint and the intercarpal--carpometacarpophalangeal joints. BID, twice daily.](annrheumdis-2015-208267f02){#ANNRHEUMDIS2015208267F2}

Secondary and exploratory endpoints {#s3c}
-----------------------------------

### RAMRIS {#s3c1}

The treatment difference (90% CI) in RAMRIS BME at month 3 was −1.24 (−2.21 to −0.27) for tofacitinib with MTX and −1.32 (−2.28 to −0.37) for tofacitinib monotherapy (both p\<0.05 vs MTX monotherapy). Significant differences were maintained to month 12 ([figure 2](#ANNRHEUMDIS2015208267F2){ref-type="fig"}A). Improvements from baseline in RAMRIS synovitis were observed in all groups up to month 12. While improvements were numerically greater in both tofacitinib groups versus MTX monotherapy at all time points assessed, differences were not generally significant ([figure 2](#ANNRHEUMDIS2015208267F2){ref-type="fig"}B). Less deterioration in RAMRIS erosion scores was noted from month 1 onwards in patients receiving tofacitinib with MTX, versus MTX monotherapy ([figure 2](#ANNRHEUMDIS2015208267F2){ref-type="fig"}C). Treatment differences (90% CI) in RAMRIS erosions at month 6 were −0.71 (−1.29 to −0.12) for tofacitinib with MTX (p\<0.05 vs MTX) and −0.67 (−1.25 to −0.08) for tofacitinib monotherapy (p=0.06 vs MTX). Corresponding changes at month 12 were −1.29 (−1.90 to −0.69) and −1.26 (−1.87 to −0.65; both p\<0.001). Mean values for all RAMRIS measures over time are presented in online [supplementary table](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-208267/-/DC1) S1.

#### Post hoc cumulative probability plots for RAMRIS endpoints {#s3c1a}

In general, more patients receiving tofacitinib showed regression (ie, improvement \<−SDC) in RAMRIS BME (month 6) and synovitis (month 3) versus MTX monotherapy, and a smaller proportion demonstrated progression (ie, deterioration \>SDC) ([figure 3](#ANNRHEUMDIS2015208267F3){ref-type="fig"}A,B). The MTX monotherapy group contained a greater proportion of patients with deterioration of erosive damage at month 12 versus both tofacitinib groups ([figure 3](#ANNRHEUMDIS2015208267F3){ref-type="fig"}C). This was mirrored by a smaller proportion of patients with no progression in van der Heijde mTSS (change ≤0.5) at month 12 in the MTX monotherapy group versus either tofacitinib groups ([figure 3](#ANNRHEUMDIS2015208267F3){ref-type="fig"}D).

![Cumulative probability plots for rheumatoid arthritis MRI score (RAMRIS) endpoints and van der Heijde modification of the total Sharp score (mTSS). The distribution of changes by percentile is shown. BID, twice daily; BME, bone marrow oedema; MCP, metacarpophalangeal; MTX, methotrexate; SDC, smallest detectable change.](annrheumdis-2015-208267f03){#ANNRHEUMDIS2015208267F3}

### RAMRIQ and DCE MRI {#s3c2}

Reductions from baseline in RAMRIQ BME and synovitis were observed for both tofacitinib groups from month 1 to month 12 ([figure 2](#ANNRHEUMDIS2015208267F2){ref-type="fig"}D,E). Treatment differences were significant (p\<0.05 vs MTX monotherapy) through month 6 for BME and through month 12 for synovitis ([figure 2](#ANNRHEUMDIS2015208267F2){ref-type="fig"}D,E). Treatment differences in RAMRIQ bone erosion scores showed significantly less deterioration of erosive damage at months 6 and 12 in both tofacitinib groups versus MTX monotherapy (all p\<0.05) ([figure 2](#ANNRHEUMDIS2015208267F2){ref-type="fig"}F).

DCE MRI measurements (N~Vox~) indicated significant improvements from baseline in synovitis at month 3 for both tofacitinib groups (p\<0.01 vs MTX monotherapy) ([figure 2](#ANNRHEUMDIS2015208267F2){ref-type="fig"}G). Improvements remained significant (p\<0.05) through month 12 ([figure 2](#ANNRHEUMDIS2015208267F2){ref-type="fig"}G). Mean values for RAMRIQ and DCE MRI measures over time can be found in online [supplementary table](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-208267/-/DC1) S1. Least squares (LS) mean changes from baseline in IRE and E~Max~ are shown in online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-208267/-/DC1) S1.

### Radiographic assessments {#s3c3}

Numerical changes from baseline in van der Heijde mTSS, joint space narrowing and erosion component scores were small in all treatment arms at months 6 and 12 ([table 2](#ANNRHEUMDIS2015208267TB2){ref-type="table"}).

###### 

Radiographic and clinical endpoints (evaluable set, LOCF)

                                        Tofacitinib 10 mg twice daily + MTX   Tofacitinib 10 mg twice daily monotherapy   MTX monotherapy
  ------------------------------------- ------------------------------------- ------------------------------------------- -----------------
  *LS mean change from baseline (SE)*                                                                                     
  van der Heijde mTSS                                                                                                     
   Month 6†                             0.44 (0.50)                           −0.14 (0.51)                                0.93 (0.52)
   Month 12‡                            0.85 (0.51)                           −0.15 (0.52)\*                              1.36 (0.54)
  JSN component score                                                                                                     
   Month 6†                             0.29 (0.34)                           −0.06 (0.35)                                0.35 (0.36)
   Month 12‡                            0.43 (0.35)                           −0.12 (0.36)                                0.71 (0.37)
  Erosion component score                                                                                                 
   Month 6†                             0.16 (0.24)                           −0.10 (0.25)                                0.58 (0.25)
   Month 12‡                            0.42 (0.25)                           −0.05 (0.26)                                0.65 (0.27)
  *Responders, % (SE)*                                                                                                    
  ACR20                                 N=35                                  N=36                                        N=37
   Month 3                              77.1 (7.1)                            66.7 (7.9)                                  56.8 (8.1)
   Month 6                              77.1 (7.1)\*                          72.2 (7.5)                                  54.1 (8.2)
   Month 12                             82.9 (6.4)                            66.7 (7.9)                                  56.8 (8.1)
  ACR50                                 N=35                                  N=36                                        N=37
   Month 3                              48.6 (8.4)                            55.6 (8.3)\*                                29.7 (7.5)
   Month 6                              57.1 (8.4)\*\*                        52.8 (8.3)\*                                27.0 (7.3)
   Month 12                             65.7 (8.0)\*\*                        50.0 (8.3)                                  35.1 (7.8)
  ACR70                                 N=35                                  N=36                                        N=37
   Month 3                              25.7 (7.4)                            27.8 (7.5)                                  13.5 (5.6)
   Month 6                              34.3 (8.0)                            30.6 (7.7)                                  24.3 (7.1)
   Month 12                             28.6 (7.6)                            33.3 (7.9)                                  24.3 (7.1)
  DAS28-4(ESR) \<2.6                    N=34                                  N=36                                        N=37
   Month 3                              23.5 (7.3)                            2.8 (2.7)                                   13.5 (5.6)
   Month 6                              29.4 (7.8)                            13.9 (5.8)                                  13.5 (5.6)
   Month 12                             35.3 (8.2)\*                          19.4 (6.6)                                  13.5 (5.6)
  DAS28-4(ESR) ≤3.2                     N=34                                  N=36                                        N=37
   Month 3                              32.4 (8.0)                            30.6 (7.7)                                  16.2 (6.1)
   Month 6                              41.2 (8.4)                            27.8 (7.5)                                  21.6 (6.8)
   Month 12                             58.8 (8.4)\*\*\*                      30.6 (7.7)                                  18.9 (6.4)
  HAQ-DI improvement ≥0.22§             N=34                                  N=36                                        N=37
   Month 3                              73.5 (7.6)                            75.0 (7.2)                                  81.1 (6.4)
   Month 6                              76.5 (7.3)                            75.0 (7.2)                                  70.3 (7.5)
   Month 12                             73.5 (7.6)                            72.2 (7.5)                                  73.0 (7.3)

\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs MTX monotherapy.

†The numbers of patients evaluable at Month 6 were 29, 27 and 28 in the tofacitinib with MTX, tofacitinib monotherapy and MTX monotherapy groups, respectively.

‡The numbers of patients evaluable at Month 12 were 26, 25 and 22 in the tofacitinib with MTX, tofacitinib monotherapy and MTX monotherapy groups, respectively.

§Improvement vs baseline.

ACR, American College of Rheumatology response criteria; DAS28-4(ESR), Disease Activity Score in 28 joints with 4 variables including erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; JSN, joint space narrowing; LOCF, last observation carried forward; LS, least squares; mTSS, van der Heijde modification of the total Sharp score; MTX, methotrexate; N, number of patients with values at baseline and time point of interest.

### Clinical response {#s3c4}

Numerically higher ACR20, ACR50 and ACR70 response rates were observed at months 3, 6 and 12 in the tofacitinib groups versus MTX monotherapy ([table 2](#ANNRHEUMDIS2015208267TB2){ref-type="table"}). The proportion of patients who achieved DAS28-4(ESR) \<2.6 increased over time in both tofacitinib groups, whereas corresponding values in the MTX monotherapy group remained low and stable ([table 2](#ANNRHEUMDIS2015208267TB2){ref-type="table"}). More patients receiving tofacitinib (vs MTX monotherapy) achieved DAS28-4(ESR) ≤3.2 from month 3 onwards ([table 2](#ANNRHEUMDIS2015208267TB2){ref-type="table"}). Compared with MTX monotherapy, the proportion of patients achieving an improvement in HAQ-DI ≥0.22 from baseline in the tofacitinib groups was numerically higher at month 6 and similar at month 12 ([table 2](#ANNRHEUMDIS2015208267TB2){ref-type="table"}).

### Safety and tolerability {#s3c5}

AEs were reported in 78.9% of patients (86/109), of which 96.1% (245/255) were mild or moderate. AEs are summarised in [table 3](#ANNRHEUMDIS2015208267TB3){ref-type="table"}. Five patients had serious AEs, one of which (anal abscess in a patient receiving tofacitinib with MTX) was considered treatment-related by the investigator, resulted in permanent discontinuation, and was the only serious infection reported. No deaths were reported. Eleven patients discontinued due to AEs (any cause). Liver function test abnormalities were the most common AE that resulted in discontinuation: two patients receiving tofacitinib with MTX, and four patients receiving MTX monotherapy. Six patients receiving MTX monotherapy discontinued due to insufficient clinical response---no tofacitinib-treated patients discontinued for this reason.

###### 

Safety events and discontinuations (all causalities)

  n (%)                                                         Tofacitinib 10 mg twice daily + MTX (N=36)   Tofacitinib 10 mg twice daily monotherapy (N=36)   MTX monotherapy (N=37)
  ------------------------------------------------------------- -------------------------------------------- -------------------------------------------------- ------------------------
  Patients with TEAEs                                           25 (69.4)                                    31 (86.1)                                          30 (81.1)
  Severity of TEAEs                                                                                                                                             
   Mild/moderate                                                89/93 (95.7)                                 83/88 (94.3)                                       73/74 (98.6)
   Severe                                                       4/93 (4.3)                                   5/88 (5.7)                                         1/74 (1.4)
  Patients with serious TEAEs                                   2 (5.6)                                      1 (2.8)                                            2 (5.4)
  Discontinuations                                              8 (22.2)                                     9 (25.0)                                           16^†^ (43.2)
   Discontinuations due to TEAEs                                4 (11.1)                                     2 (5.6)                                            5 (13.5)
  Most common TEAEs by SOC                                                                                                                                      
   Infections and infestations                                  14 (38.9)                                    10 (27.8)                                          9 (24.3)
   Gastrointestinal disorders                                   9 (25.0)                                     11 (30.6)                                          10 (27.0)
   Investigations                                               11 (30.6)                                    7 (19.4)                                           10 (27.0)
   Skin and subcutaneous tissue disorders                       5 (13.9)                                     7 (19.4)                                           5 (13.5)
   Musculoskeletal and connective tissue disorders              4 (11.1)                                     6 (16.7)                                           6 (16.2)
  Most common TEAEs occurring in ≥5% of patients in any group                                                                                                   
   Increased alanine aminotransferase                           6 (16.7)                                     0 (0.0)                                            5 (13.5)
   Hypertension                                                 1 (2.8)                                      6 (16.7)                                           0 (0.0)
   Gastritis                                                    0 (0.0)                                      5 (13.9)                                           4 (10.8)
   Rheumatoid arthritis                                         0 (0.0)                                      2 (5.6)                                            5 (13.5)
   Rash                                                         1 (2.8)                                      4 (11.1)                                           0 (0.0)
   Alopecia                                                     3 (8.3)                                      0 (0.0)                                            3 (8.1)
   Headache                                                     3 (8.3)                                      2 (5.6)                                            2 (5.4)
   Pharyngitis                                                  2 (5.6)                                      3 (8.3)                                            2 (5.4)
   Upper respiratory tract infection                            3 (8.3)                                      2 (5.6)                                            2 (5.4)
   Blood creatinine phosphokinase increased                     1 (2.8)                                      3 (8.3)                                            1 (2.7)
   Bronchitis                                                   3 (8.3)                                      0 (0.0)                                            0 (0.0)
   Aspartate aminotransferase increased                         2 (5.6)                                      1 (2.8)                                            3 (8.1)
   Influenza                                                    2 (5.6)                                      2 (5.6)                                            0 (0.0)
   Urinary tract infection                                      2 (5.6)                                      2 (5.6)                                            0 (0.0)
   Upper abdominal pain                                         2 (5.6)                                      1 (2.8)                                            2 (5.4)
   Hypertransaminasaemia                                        2 (5.6)                                      1 (2.8)                                            1 (5.4)
   Dyspepsia                                                    2 (5.6)                                      1 (2.8)                                            1 (2.7)
   Hepatic enzyme increased                                     2 (5.6)                                      1 (2.8)                                            2 (5.4)
   Rhinitis                                                     2 (5.6)                                      1 (2.8)                                            1 (2.7)
   Diarrhoea                                                    1 (2.8)                                      2 (5.6)                                            1 (2.7)
   Hypertriglyceridaemia                                        1 (2.8)                                      1 (2.8)                                            2 (5.4)
   Back pain                                                    1 (2.8)                                      0 (0.0)                                            2 (5.4)
   Gamma-glutamyl transferase increased                         1 (2.8)                                      0 (0.0)                                            2 (5.4)
   Gastroenteritis                                              2 (5.6)                                      0 (0.0)                                            0 (0.0)
   Dry mouth                                                    2 (5.6)                                      0 (0.0)                                            0 (0.0)
   Transaminase increased                                       2 (5.6)                                      0 (0.0)                                            0 (0.0)
   Weight increased                                             0 (0.0)                                      2 (5.6)                                            0 (0.0)
   Menorrhagia                                                  0 (0.0)                                      2 (5.6)                                            0 (0.0)

†Discontinuations due to: insufficient clinical response (n=6); AE (n=5; of which 3 were related to study drug); patient no longer willing to participate in study (n=3); and protocol violation (n=2).

MTX, methotrexate; N, number of patients treated; n, number of unique patients with events; SOC, system organ class; TEAEs, treatment-emergent adverse events.

There were few differences between treatment groups: nine patients (8.3%) had severe AEs, of which eight (7.3%) were randomised to tofacitinib (n=4 in each tofacitinib group); and the proportion of patients with infections (any cause) was higher for tofacitinib with MTX versus the monotherapy groups ([table 3](#ANNRHEUMDIS2015208267TB3){ref-type="table"}).

Discussion {#s4}
==========

This novel imaging study in patients with early RA provides evidence that tofacitinib 10 mg twice daily, administered as monotherapy or in combination with MTX, can improve MRI outcomes related to tissue inflammation that have been identified as prognostic indicators for joint damage.[@R1] [@R40] All MRI methodologies demonstrated reduced inflammation in the synovium and bone marrow with tofacitinib. Numerical trends in semiquantitative and quantitative MRI data were consistent between the two tofacitinib arms. Furthermore, quantitative methodologies identified significant changes in MRI pathologies (inflammation and erosive damage) as early as month 1 or 3, and demonstrated suboptimal treatment-related suppression of inflammation and progressive bone erosions with MTX monotherapy. The study met the first of its co-primary endpoints, with highly significant improvements in RAMRIS BME at month 6 observed for both tofacitinib groups versus MTX monotherapy. Statistically significant improvement in RAMRIS synovitis at month 3 versus MTX monotherapy was not met. However, numerical improvements in RAMRIS synovitis were observed in both tofacitinib groups (vs MTX). Furthermore, significant improvements in synovitis scores were observed over time with tofacitinib when quantitative methodologies were used.

The concordance between results obtained using three different MRI techniques underlines the effectiveness of MRI in the evaluation of joint inflammation and damage. All measures were analysed blind to time order, adding to the robustness of the evaluation. The improved differentiation of tofacitinib groups from MTX monotherapy enabled by the quantitative MRI techniques (compared with the semiquantitative RAMRIS method) further validates their use as improved tools for outcome assessment. RAMRIQ is still in development, and increased responsiveness for bone pathologies is expected.

In this study, changes from baseline in van der Heijde mTSS were small in both tofacitinib groups. This finding, together with the relative proportions of patients with progression in mTSS at month 12 in tofacitinib groups (vs MTX monotherapy), is supportive of the lack of radiographic progression noted in previous studies of tofacitinib as monotherapy, or in combination with MTX, in patients with moderate-to-severe RA.[@R14] [@R15] In the present study, trends in radiographic parameters at months 6 and 12 were consistent with MRI data.

The safety and efficacy of tofacitinib was consistent with phase 3 studies of tofacitinib.[@R11] No new safety signals were identified in this study.

This was an exploratory study. The RAMRIS SDCs were calculated from intraobserver readings, and this may result in more favourable SDCs than those calculated from interobserver readings. Additionally, the relatively small sample size (\<40 patients per group) may have introduced certain limitations. Furthermore, approximately half of the patients randomised to MTX monotherapy failed to complete the study. It is possible that had patients not been lost who were failing on MTX monotherapy, larger treatment differences would have been observed for tofacitinib groups versus MTX monotherapy. However, a separate analysis using last observation carried forward for missing values produced findings that were consistent with those of the evaluable set (not shown).

Conclusions {#s5}
===========

These results, obtained using a range of highly sensitive MRI endpoints, and incorporating the validated RAMRIS technique and novel quantitative techniques, provide consistent evidence for the benefits of tofacitinib in reducing inflammation in the synovium and bone marrow, and inhibiting progression of structural damage in patients with early RA. The novel, quantitative methods used here may, after further validation, prove more sensitive and discriminating than conventional semiquantitative scoring.
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